carbidopa/levodopa "fair-med" 12,5+50 mg tabletter
fair-med healthcare gmbh - carbidopa, levodopa - tabletter - 12,5+50 mg
carbidopa/levodopa "fair-med" 25+100 mg tabletter
fair-med healthcare gmbh - carbidopa, levodopa - tabletter - 25+100 mg
medicebran 20 mg tabletter
orifarm a/s - methylphenidathydrochlorid - tabletter - 20 mg
purevax felv
boehringer ingelheim vetmedica gmbh - felin leukæmi virus rekombinant canarypox virus (vcp97) - immunologicals for felidae, - katte - aktiv immunisering af katte, der er 8 uger gamle eller ældre mod feline leukæmi til forebyggelse af vedvarende viraemia og kliniske tegn på den relaterede sygdom. immunitetsbegyndelsen er påvist 2 uger efter primær vaccination. varigheden af immunitet er et år efter den sidste vaccination.
purevax rcp felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - katte - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
purevax rcpch felv
boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - katte - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.
canesten 10 mg/g vaginalcreme
bayer ab - clotrimazol - vaginalcreme - 10 mg/g
canesten 500 mg+10 mg/g vaginaltabletter og creme
bayer ab - clotrimazol - vaginaltabletter og creme - 500 mg+10 mg/g
canesten 500 mg+10 mg/g vaginaltabletter og creme
orifarm a/s - clotrimazol - vaginaltabletter og creme - 500 mg+10 mg/g
canesten 500 mg+10 mg/g vaginaltabletter og creme
2care4 aps - clotrimazol - vaginaltabletter og creme - 500 mg+10 mg/g